anticoagulants, oral factor Xa inhibitors, apixaban, 10 mg twice daily for 7 days, then 5 mg twice daily for 6 months
DISEASE INTERVENTION COMPARISON RESULTS
N Engl J Med. 2013 Aug 29;369(9):799-808 Randomized Controlled Trial, Multicenter Study
IN thromboembolic disease The Use of
anticoagulants, oral factor Xa inhibitors, apixaban, 10 mg twice daily for 7 days, then 5 mg twice daily for 6 months
As Treatment, Acute
Is equal Than
full dose LMWH enoxaparin initially, followed by warfarin
To reduce recurrent symptomatic venous thromboembolism or related death: 2.3% apixaban VS 2.7% enoxaparin+warfarin, p NS. Less major bleedings with apixaban: 0.6% apixaban VS 1.8% enoxaparin+warfarin